Drug Trial Radar · NCT05059522
Continued Access Study for Participants Deriving Benefit in Pfizer-Sponsored Avelumab Parent Studies That Are Closing
Last checked: Nov 19, 2026Latest source record: Oct 20, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
77
Actual
Start
Sep 29, 2021
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Sep 28, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This Master Protocol for Avelumab Continuation Sub-Studies is to provide continued treatment access, safety follow-up, and when applicable, overall survival follow-up for eligible participants who continue to derive a benefit from study intervention in the Pfizer-sponsored Avelumab parent studies.
Conditions
- Advanced Malignancies
- NSCLC
- Ovarian Cancer
- Urothelial Cancer
- Solid Tumors
Interventions
AvelumabDrug
oral
LorlatanibDrug
oral
TalazoparibDrug
oral
PemetrexedDrug
IV (intravenous) infusion
AxitinibDrug
oral
CMP 001Drug
IT (intratumoral) or SC (subcutaneous)
UtomilumabDrug
IV infusion
PF04518600Drug
IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with adverse events leading to permanent discontinuation of study interventionTime frame: Baseline up to approximately 5 years
- Number serious adverse events reported for all participantsTime frame: Baseline up to approximately 5 years
Locations
71 sites in 19 countries. Site status is shown where the registry gives one.
Highlands Oncology Group, PA
Fayetteville, Arkansas
Highlands Oncology Group, PA
Rogers, Arkansas
Highlands Oncology Group, PA
Springdale, Arkansas
The Regents of the University of California
Los Angeles, California
UCLA Hematology/Oncology
Los Angeles, California
Moffitt Cancer Center
Tampa, Florida
MSK Basking Ridge
Basking Ridge, New Jersey
MSK Monmouth
Middletown, New Jersey
MSK Bergen
Montvale, New Jersey
MSK Commack
Commack, New York
MSK Westchester
Harrison, New York
Memorial Sloan Kettering Cancer Center (IDS Pharmacy)
Long Island City, New York
Memorial Sloan Kettering Cancer Center - David H. Koch Center for Cancer Care (74th Street).
New York, New York
Memorial Sloan Kettering Cancer Center 53rd street.
New York, New York
Memorial Sloan Kettering Cancer Center
New York, New York
MSK Nassau
Uniondale, New York
Hospital of the University of Pennsylvania
Philadelphia, Pennsylvania
The Trustees of the University of Pennsylvania, Clinical Research (OCR)
Philadelphia, Pennsylvania
The University of Texas MD Anderson Cancer Center
Houston, Texas
Fred Hutchinson Cancer Center
Seattle, Washington
Macquarie University
North Ryde, New South Wales, Australia
Mater Hospital Sydney
Wollstonecraft, New South Wales, Australia
Melanoma Institute Australia
Wollstonecraft, New South Wales, Australia
The Prince Charles Hospital
Chermside, Queensland, Australia
Grand Hôpital de Charleroi
Gilly, Belgium
UZ Gent
Ghent, Oost-vlaanderen, Belgium
Cross Cancer Institute
Edmonton, Alberta, Canada
Kingston Health Sciences Centre-Kingston General Hospital Site
Kingston, Ontario, Canada
Aalborg Universitetshospital, Syd
Aalborg, North Denmark, Denmark
Institut de Cancérologie de Lorraine Alexis Vautrin
Vandœuvre-lès-Nancy, Lorraine, France
Országos Onkológiai Intézet
Budapest, Hungary
Rabin Medical Center
Petah Tikva, Central District, Israel
Azienda Ospedaliero Universitaria Ospedali Riuniti Umberto I - G.M. Lancisi - G. Salesi
Ancona, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Lombardy, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Milano, Italy
IRCCS Istituto Clinico Humanitas
Rozzano, Milano, Italy
National Hospital Organization Kyushu Cancer Center
Fukuoka, Japan
Oita University Hospital
Yufu, Oita Prefecture, Japan
National Cancer Center Hospital
Chuo-ku, Tokyo, Japan
Japanese Foundation for Cancer Research
Koto, Tokyo, Japan
Showing 40 of 71 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.